Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han (2016). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), pp. 56-66, DOI: 10.1016/s0140-6736(16)32453-9.
Article353 days agoSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, María Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, L Ruíz del Arbol, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix (2016). Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology, 64(5), pp. 1090-1098, DOI: 10.1016/j.jhep.2016.01.012.
Article353 days agoSorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix (2012). Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.. Journal of Clinical Oncology, 30(4_suppl), pp. LBA154-LBA154, DOI: 10.1200/jco.2012.30.4_suppl.lba154.
Article353 days agoPrediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach
Guohong Han, Sarah Berhane, Hidenori Toyoda, Dominik Bettinger, Omar Elshaarawy, Anthony W.H. Chan, Martha M. Kirstein, Cristina Mosconi, Florian Hucke, Daniel H. Palmer, David J. Pinato, Rohini Sharma, Diego Ottaviani, Jeong Won Jang, Tim A. Labeur, Otto M. van Delden, Mario Pirisi, Nick Stern, Bruno Sangro, Tim Meyer, Waleed Fateen, Marta García‐Fiñana, Asmaa Gomaa, Imam Waked, Eman Rewisha, Guruprasad P. Aithal, Simon Travis, Masatoshi Kudo, Alessandro Cucchetti, Markus Peck‐Radosavljevic, R. Bart Takkenberg, Stephen L. Chan, Arndt Vogel, Philip J. Johnson (2019). Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach. , 72(1), DOI: https://doi.org/10.1002/hep.31022.
Article15 days ago4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
Guohong Han, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean‐Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix (2018). 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. , 29(4), DOI: https://doi.org/10.1016/j.jvir.2018.01.420.
Article15 days ago